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There are limited treatment options for co-occurring sleep disorders and obsessive-
compulsive disorder (OCD). We postulated that Modafinil (Provigil) [2-{(diphenylmethyl) 
sulfinyl acetamide}] a non-amphetamine wakefulness-promoting agent, might be of value in 
patients with excessive daytime sleepiness (EDS). Randomized double-blind placebo 
controlled depression trials have investigated the effects of modafinil co-administered with 
selective serotonin re-uptake inhibitors (SSRIs) and found improvement in clinical global 
scores and, aside from effects on sleep and mood, modafinil has exhibited cognitive 
enhancing effects in some subjects (Minzenberg and Carter, 2008). In a double-blind placebo-
controlled crossover challenge, Turner et al. (2004) demonstrated decreased motor 
impulsivity as measured on laboratory tests in adult attention-deficit/hyperactivity disorder 
patients treated with single doses of modafinil (100 mg and 200 mg). To date, studies 
examining the neuropsychological effects of treatment are rare in OCD and have generally 
failed to show a positive effect of SSRI treatment on cognition (Nielen and den Boer 2003). In 
this context, we considered a new approach for treating neurocognitive impairments in 
treatment-resistant OCD. Modafinil’s effects on clinical symptoms and on a selected range of 
neurocognitive functions previously reported to be impaired in OCD (Chamberlain et al. 
2005) are examined. We report the case of a patient with treatment-resistant OCD and EDS 
treated with adjunctive modafinil. 
 DW is a 33 year old unemployed man with a 13-year history of aggressive obsessions, 
panic anxiety, low mood, and EDS. Past treatment with dothiepin, venlafaxine, and several 
SSRIs had produced little benefit. A primary diagnosis of SSRI-resistant, DSM-IV OCD 
(defined as less than 25% improvement on the Yale-Brown Obsessive-Compulsive Scale  
(Y-BOCS) despite adequate treatment trials) was made, with DSM-IV panic disorder and 
DSM-IV dysthymia as subsidiary diagnoses. His sleep schedule was chaotic, with sleeping 
 3 
 
periods during the day, though he tended to get up at 8 am irrespectively. At initiation of 
modafinil, DW (right-handed, no sensory impairments) had been receiving escitalopram 40 
mg for at least 12 weeks being administered unchanged throughout the trial. A single morning 
dose of modafinil 100 mg was prescribed and increased after three weeks to 200 mg (in two 
divided doses), and after four weeks to 400 mg (in two divided doses). Treatment adherence 
was checked verbally. Clinical assessments were performed at baseline (immediately before 
modafinil), at one week, and at four weeks after starting modafinil, using the Epworth 
Sleepiness Scale (ESS) supplemented by the patient’s own sleep-report, Y-BOCS, 
Montgomery and Åsberg Depression Rating Scale (MADRS), Sheehan Disability Scale 
(SDS), Clinical Global Impression Severity scale (CGIs), State-Trait Anxiety Inventory, 
Locus of Control Scale (LoC) as well as the National Adult Reading Test (NART). 
Neurocognitive assessment was performed at baseline and following four weeks of modafinil 
treatment (100 mg for three weeks and 200 mg for one week). Testing comprised six selected 
tasks from the Cambridge Neuropsychological Test Automated Battery (CANTAB; 
Cambridge Cognition, see Table 1) on a screen, positioned approximately 60 centimeters 
away. According to self-report, after one and four weeks’ modafinil, informants had noticed 
marginally improved daytime drowsiness compared to baseline. On objective tests, scores on 
the ESS (Baseline score (BS)=20; Week 1 (W1)=22; Week 4 (W4)=18) and the Y-BOCS 
(BS=22; W1=21; W4=20) also marginally improved and the SDS (BS=27; W1=24; W4=22) 
improved by 5 points (18%) from baseline. The CGI (BS=5; W1=5; W4=5), MADRS 
(BS=27; W1=25; W4=28), and LoC score (BS=16; W4=15) remained relatively unchanged. 
In contrast, state anxiety showed a substantial worsening by 11 points (19%) by week four 
(state – BS=57; W4=68; trait – BS=67; W4=68). His predicted verbal IQ score was 117 
assessed by the NART. After four weeks, modafinil was increased to 400 mg. After one day 
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at this dose DW telephoned to report he felt agitated, paranoid, and irritable and treatment was 
discontinued. 
 
Table 1 Neurocognitive performance at baseline and following four weeks of modafinil 
treatment, including z-scores after obtaining age-matched normative data from Cambridge 
Cognition. The z-scores quantify the patient’s score in terms of the number of standard 
deviations the score is from the mean of the normative data. A negative z-score represents 
performance below the normative mean and a positive z-score indicates a better performance.    
Variable Baseline  Age match Week 4 Age match 
Cambridge Gambling Task     
Rational decisions (%) 86 N/A 92 N/A 
Points gambled (%) 49 -0.97 67 0.55 
Spatial Recognition Memory     
Recognition (%) 75 -1.10 80 -0.56 
Spatial Working Memory     
Between-search errors 34 -0.98 27 -0.57 
Within-search errors 0 0.53 3 -0.28 
Strategy 38 -1.23 36 -0.90 
Intra/Extradimensional Set Shift     
Trials to criterion: intra  7 N/A 7 N/A 
Trials to criterion: extra 14 -0.89 10 -0.38 
Stockings of Cambridge     
Attempts 5 moves 6 0.28 7 -0.40 
Initial thinking 5 moves  4260 (ms) 0.95 5936 (ms) 0.82 
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Subsequent thinking 5 moves  2827 (ms) -1.39 409 (ms) 0.57 
Perfect solutions 9 -0.09 7 -1.03 
Affective Go/No-Go     
Total false alarms 27 N/A 11 N/A 
Reaction time  570 (ms) N/A 585 (ms) N/A 
 
 
 To our knowledge, this is the first reported case of OCD treated with modafinil. Thus, 
although typical of resistant OCD, there was potential for confounding effects of DW’s 
comorbid disorders on modafinil-responses. Being open-label, the trial was also subject to 
confounds such as rater-bias, placebo-effects, and potential learning effects on the cognitive 
tasks. After modafinil treatment for 4 weeks (100-200 mg), measures of OCD (Y-BOCS), 
EDS (ESS), and social disability (SDS) showed small but non-substantial improvements, 
whereas depression (MADRS) and clinical global impression of illness severity (CGIs) failed 
to change, and state anxiety substantially increased. In view of the treatment-resistant nature 
of this case, and the short exposure to modafinil compared to conventional treatment trials, 
the small clinical changes in OCD symptoms are encouraging. Despite increased state 
anxiety, doses of modafinil up to 200 mg were reasonably well-tolerated. State anxiety is a 
recognized adverse effect of modafinil at clinically-effective doses although it is unclear if 
this effect is dose related (Minzenberg and Carter 2008). In our patient, susceptibility to 
increased anxiety may have been related to the comorbid panic disorder. Interestingly, in our 
case, modafinil dissociated state anxiety (which worsened) from OCD (which marginally 
improved). This study was not designed to statistically evaluate cognitive effects of modafinil. 
Nonetheless, DW exhibited neurocognitive deficits at baseline compared to normative data 
where available on several tasks, including set-shifting and mnemonic function (spatial 
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recognition and spatial working memory). These deficits, in general, improved following 
modafinil treatment. Such ‘executive’ domains are thought to be subserved by dissociable 
prefrontal cortex neurocircuitry and modulated by monoaminergic tone (Sawaguchi and 
Goldman-Rakic 1991). Putative cognitive improvement contrasted with the patient’s 
subjective impression of no improvement in alertness and a worsening of state anxiety. 
Randomized trials comparing modafinil (≤200 mg), both as monotherapy and combined with 
SSRIs, with placebo and OCD patients with normal controls are indicated to clarify how far 
these changes are associated with the drug (and not simply learning effects) and how specific 
they are for OCD.  
 The mechanisms by which modafinil modulates clinical and neurocognitive indices 
have yet to be clearly delineated (Minzenberg and Carter 2008). Nevertheless, it is suggested 
that since each trial on the neurocognitive tasks (CANTAB, except perhaps set shifting), 
seems independent of its predecessors, learning effects are obviated. Also, linking the 
different positive effects in the cognitive tasks to specific learning effects seem unlikely as 
modafinil does not generally enhance associative learning (Turner et al. 2004) although it 
would be presumptuous to rule out learning in situations of repeated cognitive testing. 
However, the selective neurocognitive improvements in response accuracy (memory, set 
shifting), response suppression (affective stimuli) and decision-making seem more related to 
selective changes in behavioural sensitivity, attention and impulse control, as mediated by 
modafinil treatment, rather than to general learning effects.   
 Recently, growing evidence from translational studies questions the role of dopamine 
in modafinil’s behavioural effects (Eagle et al. 2007). Enhancing dopamine transmission in 
parallel to 5-HT and/or NA activation has been proposed as a ‘triple action’ method to 
accelerate antidepressant response (Milan 2006). Our patient was taking a stable, high dose of 
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SSRI. Co-administration of modafinil did not improve depressive ratings and was found to 
worsen anxiety, paranoia, and irritability. Moreover, co-administration of dopamimetic agents 
and SSRIs also significantly increased extracellular dopamine levels but reduced extracellular 
5-HT in rat prefrontal cortex (Weikop et al. 2007). These findings may hold relevance for our 
case; conceivably, adding modafinil to an SSRI such as escitalopram increased the cortical 
dopamine signal and thereby improved cognition, obsessions, and compulsions, but also 
attenuated cortical 5-HT neurotransmission, producing increased anxiety and paranoia. 
Further research using monoamine receptor-specific ligands may help clarify the 
neurochemical mechanisms underpinning modafinil’s clinical and neurocognitive effects in 
OCD. Findings from this case study suggest that modafinil (100-200 mg) should be 
investigated as a candidate add-on treatment for the neurocognitive deficits associated with 
OCD, which likely impede everyday functioning. 
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